About NADPH oxidase organizer 1
NADPH oxidase organizer 1 (NOXO1) is a protein
from Homo sapiens identified by UniProt accession
Q8NFA2, 376 residues long.
MolForge cross-references it against 0 known binders and
44 disease associations.
Target properties
| Protein name | NADPH oxidase organizer 1 |
| UniProt accession | Q8NFA2 |
| Gene | NOXO1 |
| Organism | Homo sapiens |
| Length | 376 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (44)
Diseases linked to this target (Open Targets).
- Red cell distribution width · score 0.14
- diabetes mellitus · score 0.05
- cardiovascular disease · score 0.05
- atherosclerosis · score 0.04
- Primary dystonia, DYT13 type · score 0.04
- chorea, childhood-onset, with psychomotor retardation · score 0.04
- stomach neoplasm · score 0.04
- intellectual disability, autosomal recessive 58 · score 0.03
- guanidinoacetate methyltransferase deficiency · score 0.03
- benign paroxysmal torticollis of infancy · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8NFA2-F1 | alphafold | PREDICTED | 63.76 | — |
Amino-acid sequence (376 residues)
MAGPRYPVSV QGAALVQIKR LQTFAFSVRW SDGSDTFVRR SWDEFRQLKK TLKETFPVEA GLLRRSDRVL PKLLGQASLD APLLGRVGRT SRGLARLQLL ETYSRRLLAT AERVARSPTI TGFFAPQPLD LEPALPPGSR VILPTPEEQP LSRAAGRLSI HSLEAQSLRC LQPFCTQDTR DRPFQAQAQE SLDVLLRHPS GWWLVENEDR QTAWFPAPYL EEAAPGQGRE GGPSLGSSGP QFCASRAYES SRADELSVPA GARVRVLETS DRGWWLCRYG DRAGLLPAVL LRPEGLGALL SGTGFRGGDD PAGEARGFPE PSQATAPPPT VPTRPSPGAI QSRCCTVTRR ALERRPRRQG RPRGCVDSVP HPTTEQ
Explore NADPH oxidase organizer 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets